FUKOKU MUTUAL LIFE INSURANCE Co Has $392,000 Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

FUKOKU MUTUAL LIFE INSURANCE Co trimmed its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 26.6% in the 4th quarter, Holdings Channel reports. The institutional investor owned 550 shares of the biopharmaceutical company’s stock after selling 199 shares during the period. FUKOKU MUTUAL LIFE INSURANCE Co’s holdings in Regeneron Pharmaceuticals were worth $392,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the company. J.W. Cole Advisors Inc. raised its stake in shares of Regeneron Pharmaceuticals by 11.5% in the 3rd quarter. J.W. Cole Advisors Inc. now owns 802 shares of the biopharmaceutical company’s stock valued at $843,000 after acquiring an additional 83 shares in the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA increased its position in shares of Regeneron Pharmaceuticals by 5.6% during the third quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 109,481 shares of the biopharmaceutical company’s stock valued at $115,091,000 after purchasing an additional 5,801 shares during the period. New York State Teachers Retirement System increased its position in shares of Regeneron Pharmaceuticals by 0.9% during the third quarter. New York State Teachers Retirement System now owns 100,427 shares of the biopharmaceutical company’s stock valued at $105,573,000 after purchasing an additional 907 shares during the period. First Trust Direct Indexing L.P. increased its position in shares of Regeneron Pharmaceuticals by 3.3% during the third quarter. First Trust Direct Indexing L.P. now owns 3,842 shares of the biopharmaceutical company’s stock valued at $4,038,000 after purchasing an additional 124 shares during the period. Finally, Pinnacle Associates Ltd. increased its position in shares of Regeneron Pharmaceuticals by 0.9% during the third quarter. Pinnacle Associates Ltd. now owns 66,965 shares of the biopharmaceutical company’s stock valued at $70,396,000 after purchasing an additional 611 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on REGN. Leerink Partnrs upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 5th. Wells Fargo & Company decreased their price target on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a research note on Friday, January 10th. UBS Group lowered Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price target for the company from $1,130.00 to $738.00 in a research note on Thursday, January 16th. Bernstein Bank decreased their price target on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. Finally, Morgan Stanley reduced their price objective on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Trading Down 2.3 %

NASDAQ:REGN opened at $706.94 on Thursday. The firm has a market capitalization of $77.29 billion, a price-to-earnings ratio of 18.47, a PEG ratio of 2.34 and a beta of 0.08. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The business’s 50-day moving average price is $698.68 and its two-hundred day moving average price is $874.30. Regeneron Pharmaceuticals, Inc. has a 1-year low of $642.00 and a 1-year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The company had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. Regeneron Pharmaceuticals’s revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the firm posted $11.86 earnings per share. On average, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.50%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.